Angiogenic and immune predictors of neoadjuvant axitinib response in renal cell carcinoma with venous tumour thrombus

Abstract Venous tumour thrombus (VTT), where the primary tumour invades the renal vein and inferior vena cava, affects 10–15% of renal cell carcinoma (RCC) patients. Curative surgery for VTT is high-risk, but neoadjuvant therapy may improve outcomes. The NAXIVA trial demonstrated a 35% VTT response...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Rebecca Wray, Hania Paverd, Ines Machado, Johanna Barbieri, Farhana Easita, Abigail R. Edwards, Ferdia A. Gallagher, Iosif A. Mendichovszky, Thomas J. Mitchell, Maike de la Roche, Jacqueline D. Shields, Stephan Ursprung, Lauren Wallis, Anne Y. Warren, Sarah J. Welsh, Mireia Crispin-Ortuzar, Grant D. Stewart, James O. Jones, On behalf of the NAXIVA Study Group
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Nature Portfolio 2025-04-01
Цуврал:	Nature Communications
Онлайн хандалт:	https://doi.org/10.1038/s41467-025-58436-8
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!